Search Results 351-360 of 16694 for alopecia

1. A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial - Mayo Clinic

   Patient must have recovered from any adverse events due to prior anti-cancer therapy (i.e., have no residual toxicities > grade 1 with the exception of alopecia ...

2. A Study to Evaluate Ribociclib Plus Letrozole to Treat Cancer of the Ovary, Fallopian Tube or Peritoneum - Mayo Clinic

   ... alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated. Patient has had major surgery within 14 days prior to starting study drug or ...

3. Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant - Mayo Clinic

   Exception to this criterion: participant with any grade of alopecia are allowed to enter in the study. Participant with Child Pugh score B or C. Participant ...

4. Seborrheic dermatitis - Symptoms and causes - Mayo Clinic

   Find out what you can do to treat this flaky skin condition that can cause scaly skin and stubborn, itchy dandruff.

5. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia. Participating Mayo Clinic ...

6. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   However, alopecia or other Grade ≤ adverse events (AEs) not constituting a safety risk based on Investigator's judgement are acceptable. Diagnosis of any ...

7. A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma - Mayo Clinic

   Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia).

8. Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 - Mayo Clinic

   Significant autoimmune disease with the exception of alopecia, vitiligo, hypothyroidism or other conditions that have never been clinically active or were ...

9. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) - Mayo Clinic

   Participants with alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency treated with ≤10 mg daily ...

10. Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer - Mayo Clinic

    ... alopecia and sensory neuropathy grade ≤ 2 is acceptable. Known severe (grade ≥ 3 NCI-CTCAE v5.0) hypersensitivity reactions to monoclonal antibodies, or ...